Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Journal of Viral Hepatitis
|
January 19, 2024
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study)
Mina S Farag, Margo J H van Campenhout, M J Sonneveld, et al.
Digestive Diseases and Sciences
|
October 17, 2018
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
Sang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
Journal of Hepatology
|
August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung, Peter Kwan, Milotka Fabri, et al.
Digestive Diseases and Sciences
|
August 24, 2018
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
Sang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
The American Journal of Gastroenterology
|
August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Henry L Y Chan, Maria Buti, Young-Suk Lim, et al.
The Lancet. Gastroenterology & Hepatology
|
February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study
Pietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection
Wai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
JHEP Reports : Innovation in Hepatology
|
January 26, 2024
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
Harry L Janssen, Young-Suk Lim, Hyung Joon Kim, et al.
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Journal of Viral Hepatitis
|
January 19, 2024
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study)
Mina S Farag, Margo J H van Campenhout, M J Sonneveld, et al.
Digestive Diseases and Sciences
|
October 17, 2018
Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
Sang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
Journal of Hepatology
|
August 23, 2016
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study
Scott Fung, Peter Kwan, Milotka Fabri, et al.
Digestive Diseases and Sciences
|
August 24, 2018
Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
Sang Hoon Ahn, Patrick Marcellin, Xiaoli Ma, et al.
The American Journal of Gastroenterology
|
August 10, 2023
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety
Henry L Y Chan, Maria Buti, Young-Suk Lim, et al.
The Lancet. Gastroenterology & Hepatology
|
February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study
Pietro Lampertico, Maria Buti, Scott Fung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection
Wai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.
JHEP Reports : Innovation in Hepatology
|
January 26, 2024
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
Harry L Janssen, Young-Suk Lim, Hyung Joon Kim, et al.
JHEP Reports : Innovation in Hepatology
|
September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.
The Lancet. Gastroenterology & Hepatology
|
April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L Y Chan, Scott Fung, Wai Kay Seto, et al.
Page
of 6